ReviewBreast care (Basel, Switzerland)2018

Late Administration of Trastuzumab Emtansine Might Lead to Loss of Chance for Better Outcome in Patients with HER2-Positive Metastatic Breast Cancer.

Luis Manso et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.